Predominantely hemorragic lesion in nAMD and response to Anti-VEGF treatment

Author: João Nassaralla (Brazil)

Co-authors: Miguel Amaro, Mario Mota, Teruo Aihira, Cristina Muccioli, Arthur Nassaralla

Purpose

To assess the prognosis of nAMD with hemorragic choroidal neovascularization treated withranibizumab, bevacizumab and aflibercept

Setting/Venue

Instituto de Olhos de Goiania - Goias - Brazil

Methods

We investigated twelve nonconsecutive cases of nAMD with predominantely hemorragicneovascularization over the course of six years. During the investigation, we looked for signs of worsening orimprovement in patient’s vision and for difference between the chose drugs results

Results

During the treatment, we found a satisfatory response of the eyes suffering from nAMD withhemorragic choroidal neovascularization when treated with anti VEGF drugs. The first signs of improvementwere noticed three months following the initial therapy and the patient who took the longest to showimprovement after the begining of the treatment did so after eight months. No patient showed imediateresponse to the treatment and no difference between the drugs were noticed during the treatment.

Conlusions

These cases of nAMD with hemorragic choroidal neovascularization benefited from thetreatment with anti VEGF, despite its first responses being held after three months of treatment. No differencein the result between drugs was noticed. 70% of the eyes treated showed improvement in the visual acuity.Two of the cases evolved to subretinal fibrosis. nAMD is still an important therapy in patients of nAMD

Financial Disclosure

Bayer, Novartis, Genon, Latinofarma, Ofta - products research

Comments

-